Filtered By:
Drug: Coumadin
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 683 results found since Jan 2013.

708 Stroke Prevention by Non-vitamin K Oral Anticoagulant (NOAC) Agents in the Absence of Atrial Fibrillation: Meta-analysis of Randomized Controlled Trials
Anticoagulation to prevent stroke is a mainstay of atrial fibrillation (AF) management. Use of warfarin in sinus rhythm reduces stroke rates, but with an increase in bleeding. The efficacy and safety of NOACs has not been studied.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: K. Lander, P. Thakeria, A. Ha, S. Nayyar Source Type: research

End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience Original Articles
Conclusions— The excess of events at EOS was likely because of a period of inadequate anticoagulation in rivaroxaban participants switched to vitamin K antagonist therapy. If transition from rivaroxaban to vitamin K antagonist is needed, timely monitoring and careful dosing should be used to ensure consistent and adequate anticoagulation.
Source: Circulation: Cardiovascular Quality and Outcomes - July 16, 2013 Category: Cardiology Authors: Mahaffey, K. W., Hellkamp, A. S., Patel, M. R., Hannan, K. L., Schwabe, K., Nessel, C. C., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Becker, R. C., Piccini, J. P., Breithardt, G., Hacke, W., Singer, D. E., Califf, R. M., Fox, K. A. A. Tags: Platelet function inhibitors, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke, Anticoagulants Original Articles Source Type: research

Benefits of non –vitamin K antagonist oral anticoagulants in patients with atrial fibrillation go beyond stroke prevention
The last decade has produced a large body of robust randomized controlled trial (RCT) data investigating the use of non –vitamin K antagonist oral anticoagulants (NOACs) in nonvalvular atrial fibrillation (AF).1–4 Compared with warfarin, dabigatran and apixaban have been found to reduce the combined outcome of stroke and systemic embolism. In addition, apixaban and edoxaban significantly reduce major bleeding. Fu rthermore, a pooled meta-analysis has demonstrated superior efficacy and overall safety of the NOACs.
Source: Heart Rhythm - January 15, 2017 Category: Cardiology Authors: Jay A. Montgomery, Gregory F. Michaud Tags: Editorial Commentary Source Type: research

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
PMID: 28264892 [PubMed - in process]
Source: Circulation - March 6, 2017 Category: Cardiology Authors: Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KA, Patel MR, ROCKET AF Steering Committee and Investigators Tags: Circulation Source Type: research

Appropriate dosing of non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation
The development of non-Vitamin K antagonist oral anticoagulants (NOACs) has been a major advance in therapy for patients requiring oral anticoagulation, particularly for long-term indications such as stroke prevention in atrial fibrillation (AF). The NOACs are generally easier to dose and manage due to less heterogeneity of effect across individuals and fewer drug and food interactions, compared with warfarin. However, the treatment effect of NOACs may vary based on important patient characteristics, particularly renal function.
Source: Trends in Cardiovascular Medicine - June 19, 2017 Category: Cardiology Authors: Benjamin A. Steinberg, Jeffrey B. Washam Source Type: research

Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding
ConclusionsThe comparative cost effectiveness of edoxaban and warfarin is highly sensitive to TTR. At the $US100,000/QALY willingness-to-pay threshold, our results suggest that warfarin is the most cost-effective treatment for patients who can achieve a TTR of 70%.
Source: American Journal of Cardiovascular Drugs - May 9, 2018 Category: Cardiology Source Type: research

Safety of Endovascular Thrombectomy for Acute Ischaemic Stroke in Anticoagulated Patients Ineligible for Intravenous Thrombolysis
Conclusion: Mechanical thrombectomy appears to be safe and effective in anticoagulated patients ineligible for thrombolysis, with observed haemorrhage rates similar to those of patients not on anticoagulant therapy. However, further multicentre prospective studies are needed, due to the rising number of patients on warfarin and DOACs worldwide.Cerebrovasc Dis 2018;46:193 –199
Source: Cerebrovascular Diseases - November 1, 2018 Category: Neurology Source Type: research

Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Authors: PMID: 30566008 [PubMed - in process]
Source: Circulation - December 18, 2018 Category: Cardiology Tags: Circulation Source Type: research

Persisting stroke risk in patients with atrial fibrillation despite proper anticoagulation – Unmet clinical needs
Oral anticoagulation (OAC) is crucial to prevent cardioembolic stroke in patients with atrial fibrillation (AF). Development of the direct oral anticoagulants (DOAC), which inhibit activities of the coagulant proteases thrombin and activated factor X (FXs), has improved the safety and efficacy of anticoagulation in AF, compared to traditional vitamin K antagonists like warfarin [1,2]. Yet in a small, but numerically relevant proportion of up to 2% of patients, this cornerstone principle fails for unclear reasons.
Source: International Journal of Cardiology - August 6, 2022 Category: Cardiology Authors: Florian Bruns, Dobromir Dobrev, Anke C. Fender Tags: Editorial Source Type: research

Racial and Ethnic Disparities in Stroke Prevention for Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting around 2% of the population (1,2) and increasing the risk of stroke by 4 to 5 times (3). Anticoagulation with Vitamin K antagonists (VKAs) such as Warfarin (4) or the newer Direct Oral Anticoagulants (DOACs) (4,5) reduces this risk by up to 60%. AF-related strokes also tend to be more severe and disabling (6).
Source: The American Journal of Medicine - December 7, 2022 Category: General Medicine Authors: Peter Calvert, Kamala Tamirisa, Amin Al-Ahmad, Gregory Y H Lip, Dhiraj Gupta Tags: Review Source Type: research

Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country
ConclusionsIn a developing country where suboptimal anticoagulation control is common, apixaban was the cost-effective alternative to warfarin for patients with both low and intermediate TTR control.
Source: American Journal of Cardiovascular Drugs - February 3, 2023 Category: Cardiology Source Type: research

Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
Expert Rev Clin Pharmacol. 2023 Mar 2. doi: 10.1080/17512433.2023.2187376. Online ahead of print.ABSTRACTINTRODUCTION: In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial fibrillation (AF). DOAC are substrates for P-glycoprotein (P-gp), CYP3A4 and CYP2C9. The activity of these enzymes is modulated by several drugs which might induce pharmacokinetic drug-drug interactions (DDI). Drugs affecting platelet function have the potential for pharmacodynamic DDI of DOAC.AREAS COVERED: The literature was searched fo...
Source: Expert Review of Clinical Pharmacology - March 2, 2023 Category: Drugs & Pharmacology Authors: Claudia St öllberger Birke Schneider Josef Finsterer Source Type: research